Rapaflo Approved for Enlarged Prostate

The leading reason men visit urologists

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

THURSDAY, Oct. 9, 2008 (HealthDay News) -- The once-daily alpha blocker Rapaflo (silodosin) has been approved by the U.S. Food and Drug Administration to treat benign prostatic hyperplasia (BPH), the medical term for an enlarged prostate.

BPH is the top reason men visit urologists. Symptoms include decreased urine flow, more frequent urination, and excessive urination at night (nocturia).

The likelihood of developing the condition increases as men age, and more than 90 percent of men over age 80 probably have BPH, according to the U.S. National Library of Medicine.

Rapaflo causes the smooth muscles of the prostate to relax, leading to improved urine flow, the manufacturer, Watson Pharmaceuticals, said in a news release. Common side effects include retrograde ejaculation (a condition in which semen enters the bladder during ejaculation) and dizziness.

More information

To learn more about BPH, visit Medline Plus.


Last Updated: